[The use of bifidumbacterin in the prevention of mastitis].
The efficiency of bifidumbacterin was studied in 160 parturients and 160 newborn for the prophylaxis of postpartum lactation mastitis and purulent-septic diseases in the infants 6 months after discharge from the hospital. The incidence of mastitis reduced from 6.88 to 1.25% while the morbidity in the newborn reduced three times. The agent does not inhibit the residence microflora of the breasts, favours early development of bifidoflora of the intestine in the new-born.
Sytnik
S I
SI
Panichev
V A
VA
Dautov
A G
AG
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use*; D001940:Breast / Q000187:drug effects / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology / Q000517:prevention & control; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008413:Mastitis / Q000382:microbiology / Q000517:prevention & control*; D011645:Puerperal Infection / Q000382:microbiology / Q000517:prevention & control; D012867:Skin / Q000187:drug effects / Q000382:microbiology; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control
D000890:Anti-Infective Agents; D001688:Biological Products; C010546:bifidobacterin
Primenenie bifidumbakterina v profilaktike mastita.